A committee of the European Medicines Agency (EMA) has recommended the conditional approval of Tecartus (brexucabtagene autoleucel) for the treatment of adults with relapsed or refractory mantle cell lymphoma (MCL). The recommendation by the Committee for Medicinal Products for Human Use (CHMP) for Kite Pharma‘s CAR T-cell therapy is specific for patients who received at least two prior lines of therapy, including a Bruton’s tyrosine kinase inhibitor (BTKi). A conditional marketing authorization is given to medicines that fulfil a…
You must be logged in to read/download the full post.
The post Tecartus Recommended for EU Approval as CAR T-cell Therapy for Mantle Cell Lymphoma appeared first on BioNewsFeeds.